MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2143/ac.65.2.2047052

Медицинская библиотека · Acta cardiologica · 2010

Cardiopulmonary involvement in Fabry's disease.

Koskenvuo Juha W, Kantola Ilkka M, Nuutila Pirjo, Knuuti Juhani, Parkkola Riitta, Mononen Ilkka, Hurme Saija, Kalliokoski Riikka, Viikari Jorma S, Wendelin-Saarenhovi Maria, Kiviniemi Tuomas O, Hartiala Jaakko J

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Fabry's disease is an X-linked lysosomal storage disease caused by deficiency of alpha-galactosidase A enzyme activity. Decreased enzyme activity leads to accumulation of glycosphingolipid in different tissues, including endothelial and smooth-muscle cells and cardiomyocytes.

OBJECTIVES

There is controversial data on cardiopulmonary involvement in Fabry's disease, because many reports are based on small and selected populations with Fabry's disease. Furthermore, the aetiology of cardiopulmonary symptoms in Fabry's disease is poorly understood.

METHODS

We studied cardiopulmonary involvement in seventeen patients with Fabry's disease (20-65 years, 6 men) using ECG, bicycle stress, cardiac magnetic resonance imaging, spirometry, diffusing capacity and pulmonary high-resolution computed tomography (HRCT) tests. Cardiopulmonary symptoms were compared to observed parameters in cardiopulmonary tests.

RESULTS

Left ventricular hypertrophy (LVH) and reduced exercise capacity are the most apparent cardiac changes in both genders with Fabry's disease. ECG parameters were normal when excluding changes related to LVH. Spirometry showed mild reduction in vital capacity and forced expiratory volume in one second (FEV I), and mean values in diffusing capacity tests were within normal limits. Generally, only slight morphological pulmonary changes were detected using pulmonary HRCT, and they were not associated with changes in pulmonary function. The self-reported amount of pulmonary symptoms associated only with lower ejection fraction (P < 0.001) and longer QRS-duration (P = 0.04) of all measured cardiopulmonary parameters, whereas cardiac symptoms have no statistically significant association with any of these parameters.

CONCLUSION

LVH and reduced exercise capacity are the most apparent cardiopulmonary changes in Fabry's disease but they have only a minor association to cardiopulmonary symptoms.Therefore, routine cardiopulmonary evaluation in Fabry's disease using echocardiography is maybe enough when integrated to counselling for aerobic exercise training.

Для цитирования: Koskenvuo Juha W, Kantola Ilkka M, Nuutila Pirjo, Knuuti Juhani, Parkkola Riitta, Mononen Ilkka, Hurme Saija, Kalliokoski Riikka, Viikari Jorma S, Wendelin-Saarenhovi Maria, Kiviniemi Tuomas O, Hartiala Jaakko J. Cardiopulmonary involvement in Fabry's disease.. Acta cardiologica. 2010. DOI: 10.2143/ac.65.2.2047052.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.